Additional Table 5 | Characteristics of non-deteriorated and deteriorated patients at baseline (Full Analysis Set, _n_ = 80). Data are mean (s.d.) values at baseline. _P_-values of between-group differences at baseline were assessed by Anova. *$P < 0.05$; Shading = best mean value at baseline within non-deteriorated and deteriorated patients. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity.

	a - Baseline in PXT3003 HD			b - Baseline in Placebo		
	Non-deteriorated (_n_ = 15)	Deteriorated (_n_ = 4)	_P_-value	Non-deteriorated (_n_ = 10)	Deteriorated (_n_ = 9)	_P_-value
CMTNS	13.3 (3.2)	16.0 (3.6)	0.16	15.0 (3.1)	13.6 (4.6)	0.42
ONLS	3.5 (0.8)	3.8 (0.5)	0.63	3.3 (0.8)	2.9 (1.4)	0.43
6MWT (m)	448.3 (67.8)	358.0 (109.5)	0.052	446.3 (97.3)	490.2 (103.3)	0.37
9HPT (s)	20.5 (7.9)	21.9 (8.3)	0.76	16.8 (2.3)	17.6 (2.7)	0.46
Ankle Dorsiflexion (Nm)	8.0 (5.5)	8.9 (8.8)	0.79	7.7 (8.0)	7.9 (5.0)	0.94
Grip (kg)	22.5 (10.4)	13.5 (7.8)	0.13	23.1 (11.2)	21.9 (10.7)	0.81
CMAP (milliV)	3.8 (2.0)	1.8 (3.1)	0.14	4.0 (1.9)	3.3 (2.2)	0.47
MCV (m/s)	22.5 (3.5)	14.7 (5.7)	0.0051*	21.1 (4.1)	22.1 (3.0)	0.58
DML (ms)	7.6 (1.4)	10.2 (2.4)	0.010*	8.4 (1.3)	8.9 (3.0)	0.64
SNAP (microV)	2.4 (2.8)	1.4 (2.8)	0.54	2.7 (3.4)	2.5 (3.1)	0.91
SCV (m/s)	30.3 (8.6)	28.2 (NA)	0.83	24.4 (5.1)	35.1 (17.8)	0.36